Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors

Strahlentherapie und Onkologie

Volumn 179, Issue 8, 2003, Pages 527-534

  Schäfer, Ulrich ^a   Micke, Oliver ^b   Müller, Stefan Bodo ^b   Schüller, Patrick ^b   Willich, Normann ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NONE

Author keywords

Anemia; Head and neck tumor; Irradiation

Indexed keywords

ADJUVANT THERAPY; ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HEAD TUMOR; HEMOGLOBIN DETERMINATION; HISTOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NECK TUMOR; PERFORMANCE; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; SEX;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0042591565     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1117-x     Document Type: Article

References (39)

1. Ang KK, Peters LJ, Weber RS, Maor MH, Morrison WH, Wendt CD, Brown BW. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 1990; 19:1339-45.
2. Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschläger C, Feldmann HJ, Molls M, Dunst J. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-66.
3. Bentzen SM, Johansen LV, Overgaard J, Thames HD. Clinical radiobiology of squamous cell carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 1991;20:1197-206.
4. Bryne M, Eide GE, Lilleng R, Langmark F, Thrane PS, Dabelsteen E. A multivariate study of the prognosis of oral squamous cell carcinomas. Are blood group and hemoglobin new prognostic factors? Cancer 1991;68: 1994-8.
5. Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986;12:2047-50.
6. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset J-M. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996;201:553-8.
7. Dunst J, Becker A, Lautenschlager C, Markau S, Becker H, Fischer K, Haensgen G. Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol 2002;178:436-41.
8. Dunst J, Stadler P, Becker A, Kuhnt T, Lautenschlager C, Molls M, Haensgen G. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 2000;177:469-73.
9. Dusenbery K-E, McGuire W-A, Holt P-J, Carson L-F, Fowler J-M, Twiggs L-B, Potish R-A. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994;29:1079-84.
10. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995; 13:2077-83.
11. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 1998;174:Suppl 4:31-4.
12. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-15.
13. Grabenbauer GG, Rodel C, Brunner T, Schulze-Mosgau S, Strnad V, Muller RG, Iro H, Sauer R. Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997. Strahlenther Onkol 2001;177:338-44.
14. Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P, eds. Blood perfusion and microenvironment of human tumors. Berlin-Heidelberg-New York: Springer: 1998; 102-12.
15. Green MR, Cox JD, Ardizzoni A, Arriagada R, Bureau G, Darwish S, Deneffe G, Fukuoka M, Joseph D, Komaki R, et al. Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report. Lung Cancer: 1994;11:Suppl 3:S11-3.
16. Henke M, Guttenberger R, Barke A, Pajonk F, Pötter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999;50:185-90.
17. Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, Tseng CJ, Chang TC, Tang SG. The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 1998;41: 823-30.
18. Kagei K, Shirato H, Nishioka T, Kitahara T, Suzuki K, Tomita M, Takamura A, Arimoto T, Matsuoka S, Mizoe JE, Sakuragi N, Fujimoto S, Miyasaka K. High-dose-rate intracavitary irradiation using linear source arrangement for stage II and III squamous cell carcinoma of the uterine cervix. Radiother Oncol 1998;47:207-13.
19. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-63.
20. Lammering G, Carl UM, Pape H, Hartmann KA. [Changes in hemoglobin concentrations in combined radio- and chemotherapy in locally advanced ORL tumors.] Strahlenther Onkol 1999;175:559-62.
21. Lavey R-S, Dempsey W-H. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27: 1147-52.
22. Lee WR, Berkey B, Marcial V, Fu K-K, Cooper J-S, Vikram B, Coia L-R, Rotman M, Ortiz H. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-75.
23. Moliterno AR, Spivak JL. Anemia of cancer. Hematol Oncol Clin North Am 1996;10:345-63.
24. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998;174:Suppl 4:13-6.
25. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
26. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 1998;46: 135-46.
27. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977;35:1-39.
28. 2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 2001;177:462-8.
29. Schäfer U, Micke O, Schueller P, Willich N. Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy - results of a prospective study. Radiology 2000; 216:371-6.
30. Schäfer U, Schuller P, Micke O, Willich N. Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer. Acta Oncol 2000;39:523-8.
31. Spiro IJ, Rice GC, Durand RE, Stickler R, Ling CC. Cell killing, radiosensitization and cell cycle redistribution induced by chronic hypoxia. Int J Radiat Oncol Biol Phys 1984;10:1275-80.
32. Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys 1997;38:1007-11.
33. Vaupel P, Thews O, Mayer A, Hockel S, Hockel M. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-31.
34. Vokes EE, Panje WR, Weichselbaum RR, Schilsky RL, Moran WJ, Awan AM, Guarnieri CM. Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg 1988;98:295-8.
35. Wagner W, Hermann R, Hartlapp J, Esser E, Christoph B, Muller MK, Krech R, Koch O. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radiochemotherapy and surgery. Strahlenther Onkol 2002;176:73-80.
36. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41:347-53.
37. Wendt T-G. Bessere Tumorkontrolle durch simultane Radiochemotherapie bei fortgeschrittenen Kopf-Hals-Karzinomen. Strahlenther Onkol 1999; 175:473-4.
38. Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-24.
39. Weppelmann B, Wheeler RH, Peters GE, Kim RY, Spencer SA, Meredith RF, Salter MM. Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. Int J Radiat Oncol Biol Phys 1992;22:1051-6.